BDX vs ZBH

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). Zimmer Biomet Holdings, Inc. (ZBH) offers the better valuation at 23. 3x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zimmer Biomet Holdings, Inc.

(ZBH) is the cheapest at 23. 3x versus Becton, Dickinson and Company at 24. 8x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 8x.

Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +10.

4%, compared to -47. 9% for Zimmer Biomet Holdings, Inc. (ZBH). Over 10 years, the gap is even starker: BDX returned +72. 9% versus ZBH's -17. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zimmer Biomet Holdings, Inc.

(ZBH) is the lower-risk stock at 0. 65β versus Becton, Dickinson and Company's 0. 66β — meaning BDX is approximately 1% more volatile than ZBH relative to the S&P 500. On balance sheet safety, Zimmer Biomet Holdings, Inc. (ZBH) carries a lower debt/equity ratio of 59% versus 76% for Becton, Dickinson and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus 7. 2% for Zimmer Biomet Holdings, Inc. (ZBH). On earnings-per-share growth, the picture is similar: Becton, Dickinson and Company grew EPS -0. 5% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, ZBH leads at 5. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zimmer Biomet Holdings, Inc.

(ZBH) is the more profitable company, earning 8. 6% net margin versus 7. 7% for Becton, Dickinson and Company — meaning it keeps 8. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZBH leads at 16. 5% versus 11. 8% for BDX. At the gross margin level — before operating expenses — ZBH leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zimmer Biomet Holdings, Inc.

(ZBH) trades at 9. 8x forward P/E versus 11. 6x for Becton, Dickinson and Company — 1. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BDX: 19. 4% to $172. 85.

All stocks in this comparison pay dividends.

Becton, Dickinson and Company (BDX) offers the highest yield at 2. 9%, versus 1. 2% for Zimmer Biomet Holdings, Inc. (ZBH).

For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66), 2. 9% yield). Both have compounded well over 10 years (BDX: +72. 9%, ZBH: -17. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.